Docetaxel in combination with prednisolone for hormone refractory prostate cancer

Hiroki Ide, Eiji Kikuchi, Hidaka Kono, Hirohiko Nagata, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima, Mototsugu Oya

研究成果: Article

13 引用 (Scopus)

抄録

Objective: The objective of this study was to evaluate the efficacy and toxicity of docetaxel in combination with prednisolone in Japanese patients with hormone refractory prostate cancer. Methods: Twenty patients with hormone refractory prostate cancer (HRPC) were administered a treatment regimen consisting of docetaxel 75 mg/m2 once every 3 or 4 weeks and prednisolone 5 mg twice daily at our institution between 2006 and 2008. Results: The patients received a median of 5.5 cycles of treatment (range, 2-12 cycles). Nine of the 20 patients (45%) had a ≥50% decrease in serum prostate-specific antigen (PSA). The median duration of response was 4 months (range, 1-11 months). The number of cycles performed, the presence of bone metastasis and the extent of disease had statistically significant associations with the response. Three patients had a transient PSA rise among the patients who ultimately had a response. Grade 3/4 leukopenia and neutropenia occurred in 80.0% and 85.0% of the patients, respectively. Interstitial pneumonia occurred in only one patient; however, the patient recovered. Finally, no treatment-related deaths were seen during the observation period. Conclusions: The combination of docetaxel 75 mg/m2 every 3 weeks and prednisolone 10 mg daily was effective and well tolerated in Japanese patients with HRPC. The results of this study suggest that a decision concerning discontinuation of this treatment should be carefully considered because a transient PSA rise was observed. Although interstitial pneumonia was rare, the potential risk of its development should be taken into consideration.

元の言語English
記事番号hyp126
ジャーナルJapanese Journal of Clinical Oncology
40
発行部数1
DOI
出版物ステータスPublished - 2009 10 16

Fingerprint

docetaxel
Prednisolone
Prostatic Neoplasms
Hormones
Prostate-Specific Antigen
Interstitial Lung Diseases
Leukopenia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

これを引用

Docetaxel in combination with prednisolone for hormone refractory prostate cancer. / Ide, Hiroki; Kikuchi, Eiji; Kono, Hidaka; Nagata, Hirohiko; Miyajima, Akira; Nakagawa, Ken; Ohigashi, Takashi; Nakashima, Jun; Oya, Mototsugu.

:: Japanese Journal of Clinical Oncology, 巻 40, 番号 1, hyp126, 16.10.2009.

研究成果: Article

Ide, H, Kikuchi, E, Kono, H, Nagata, H, Miyajima, A, Nakagawa, K, Ohigashi, T, Nakashima, J & Oya, M 2009, 'Docetaxel in combination with prednisolone for hormone refractory prostate cancer', Japanese Journal of Clinical Oncology, 巻. 40, 番号 1, hyp126. https://doi.org/10.1093/jjco/hyp126
Ide, Hiroki ; Kikuchi, Eiji ; Kono, Hidaka ; Nagata, Hirohiko ; Miyajima, Akira ; Nakagawa, Ken ; Ohigashi, Takashi ; Nakashima, Jun ; Oya, Mototsugu. / Docetaxel in combination with prednisolone for hormone refractory prostate cancer. :: Japanese Journal of Clinical Oncology. 2009 ; 巻 40, 番号 1.
@article{a2b2d4b21ac945aa9bdbaa92966e9b4a,
title = "Docetaxel in combination with prednisolone for hormone refractory prostate cancer",
abstract = "Objective: The objective of this study was to evaluate the efficacy and toxicity of docetaxel in combination with prednisolone in Japanese patients with hormone refractory prostate cancer. Methods: Twenty patients with hormone refractory prostate cancer (HRPC) were administered a treatment regimen consisting of docetaxel 75 mg/m2 once every 3 or 4 weeks and prednisolone 5 mg twice daily at our institution between 2006 and 2008. Results: The patients received a median of 5.5 cycles of treatment (range, 2-12 cycles). Nine of the 20 patients (45{\%}) had a ≥50{\%} decrease in serum prostate-specific antigen (PSA). The median duration of response was 4 months (range, 1-11 months). The number of cycles performed, the presence of bone metastasis and the extent of disease had statistically significant associations with the response. Three patients had a transient PSA rise among the patients who ultimately had a response. Grade 3/4 leukopenia and neutropenia occurred in 80.0{\%} and 85.0{\%} of the patients, respectively. Interstitial pneumonia occurred in only one patient; however, the patient recovered. Finally, no treatment-related deaths were seen during the observation period. Conclusions: The combination of docetaxel 75 mg/m2 every 3 weeks and prednisolone 10 mg daily was effective and well tolerated in Japanese patients with HRPC. The results of this study suggest that a decision concerning discontinuation of this treatment should be carefully considered because a transient PSA rise was observed. Although interstitial pneumonia was rare, the potential risk of its development should be taken into consideration.",
keywords = "Chemotherapy, Docetaxel, Prostate cancer",
author = "Hiroki Ide and Eiji Kikuchi and Hidaka Kono and Hirohiko Nagata and Akira Miyajima and Ken Nakagawa and Takashi Ohigashi and Jun Nakashima and Mototsugu Oya",
year = "2009",
month = "10",
day = "16",
doi = "10.1093/jjco/hyp126",
language = "English",
volume = "40",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Docetaxel in combination with prednisolone for hormone refractory prostate cancer

AU - Ide, Hiroki

AU - Kikuchi, Eiji

AU - Kono, Hidaka

AU - Nagata, Hirohiko

AU - Miyajima, Akira

AU - Nakagawa, Ken

AU - Ohigashi, Takashi

AU - Nakashima, Jun

AU - Oya, Mototsugu

PY - 2009/10/16

Y1 - 2009/10/16

N2 - Objective: The objective of this study was to evaluate the efficacy and toxicity of docetaxel in combination with prednisolone in Japanese patients with hormone refractory prostate cancer. Methods: Twenty patients with hormone refractory prostate cancer (HRPC) were administered a treatment regimen consisting of docetaxel 75 mg/m2 once every 3 or 4 weeks and prednisolone 5 mg twice daily at our institution between 2006 and 2008. Results: The patients received a median of 5.5 cycles of treatment (range, 2-12 cycles). Nine of the 20 patients (45%) had a ≥50% decrease in serum prostate-specific antigen (PSA). The median duration of response was 4 months (range, 1-11 months). The number of cycles performed, the presence of bone metastasis and the extent of disease had statistically significant associations with the response. Three patients had a transient PSA rise among the patients who ultimately had a response. Grade 3/4 leukopenia and neutropenia occurred in 80.0% and 85.0% of the patients, respectively. Interstitial pneumonia occurred in only one patient; however, the patient recovered. Finally, no treatment-related deaths were seen during the observation period. Conclusions: The combination of docetaxel 75 mg/m2 every 3 weeks and prednisolone 10 mg daily was effective and well tolerated in Japanese patients with HRPC. The results of this study suggest that a decision concerning discontinuation of this treatment should be carefully considered because a transient PSA rise was observed. Although interstitial pneumonia was rare, the potential risk of its development should be taken into consideration.

AB - Objective: The objective of this study was to evaluate the efficacy and toxicity of docetaxel in combination with prednisolone in Japanese patients with hormone refractory prostate cancer. Methods: Twenty patients with hormone refractory prostate cancer (HRPC) were administered a treatment regimen consisting of docetaxel 75 mg/m2 once every 3 or 4 weeks and prednisolone 5 mg twice daily at our institution between 2006 and 2008. Results: The patients received a median of 5.5 cycles of treatment (range, 2-12 cycles). Nine of the 20 patients (45%) had a ≥50% decrease in serum prostate-specific antigen (PSA). The median duration of response was 4 months (range, 1-11 months). The number of cycles performed, the presence of bone metastasis and the extent of disease had statistically significant associations with the response. Three patients had a transient PSA rise among the patients who ultimately had a response. Grade 3/4 leukopenia and neutropenia occurred in 80.0% and 85.0% of the patients, respectively. Interstitial pneumonia occurred in only one patient; however, the patient recovered. Finally, no treatment-related deaths were seen during the observation period. Conclusions: The combination of docetaxel 75 mg/m2 every 3 weeks and prednisolone 10 mg daily was effective and well tolerated in Japanese patients with HRPC. The results of this study suggest that a decision concerning discontinuation of this treatment should be carefully considered because a transient PSA rise was observed. Although interstitial pneumonia was rare, the potential risk of its development should be taken into consideration.

KW - Chemotherapy

KW - Docetaxel

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=77449083103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449083103&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyp126

DO - 10.1093/jjco/hyp126

M3 - Article

C2 - 19837689

AN - SCOPUS:77449083103

VL - 40

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

M1 - hyp126

ER -